ABSTRACT
Dose verification as part of plan checking is a critical component of high quality patient care. IMSure QA is a software platform used at the BC Cancer Agency that facilitates dose verification for both conformal and IMRT plans. We have recently initiated treating breast tangents using IMRT at the Fraser Valley Centre and noted increased dose discrepancies (mean difference of -3%) between Eclipse and IMSure's QA module. We identified two potential sources of error: air flash and tissue heterogeneity. We extend our generated fluences 3cm past the breast contour and into air to account for breathing, set-up uncertainties and swelling. IMSure does not account for the fluence in air or air flash. We present an air-flash-correction factor based on the ratios of TMRs and Phantom Scatter Factors which use the field sizes of fields with and without the air flash. In addition, we present a method to improve the heterogeneity correction used by IMSure to better match that used by AAA. Effectively we remove the IMSure's inherent heterogeneity correction and manually apply a AAA-based heterogeneity-correction factor. We evaluated our correction factors on a sample of 8 patients (32 fields) using ANOVA methods to determine which dose corrections most accurately reproduce Eclipse's values. We found the air-flash correction coupled with IMSure's inherent-heterogeneity correction has the best dose accuracy (mean difference improved from -3% to 0.3%). The AAA-heterogeneity correction alone also improved the accuracy (mean difference improved from -3% to - 1.5%), which is acceptable for plan checking purposes.
